<DOC>
	<DOCNO>NCT03006952</DOCNO>
	<brief_summary>This study design assess efficacy add pentoxifylline losartan comparison increase dose losartan type 2 diabetes patient nephropathy . also effect pentoxifylline N terminal brain natriuretic peptide ( NT-pro BNP ) C-reactive protein</brief_summary>
	<brief_title>Add-on Pentoxifylline Losartan Versus Increasing Dose Losartan NT-PRO BNP Type 2 Diabetics With Nephropathy</brief_title>
	<detailed_description>Addition pentoxifylline losartan provide antiproteinuric effect type 2 diabetes patient nephropathy might relate effect N terminal brain natriuretic peptide ( NT-pro BNP ) C-reactive protein . Pentoxifylline phosphodiestrase inhibitor anti-inflammatory effect use type 2 diabetes patient nephropathy treatment diabetes complication . NT-Pro BNP , release heart due wall stress pressure , know diagnostic prognostic marker heart failure cardiovascular mortality type 2 diabetes .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>age &gt; 30 age &lt; 70 , urinary albumin excretion ( UAE ) ≥150 mg/24 h infectious malignant disease , nondiabetic kidney disease , retinal hemorrhage , acute myocardial infarction , uncontrolled hypertension , pregnancy , unable follow , hyperthyroidism , baseline serum potassium concentration ≥5.5 meq/L , glomerular filtration rate ( GFR ) &lt; 30mL/min/1.73 intolerance pentoxifylline</criteria>
	<gender>All</gender>
	<minimum_age>38 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>